Key facts
- This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Apr 2022, 16:05.
Dror Bashan - 11 Apr 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- PLX
- Reported as of
- 11 Apr 2022
- Net transaction value
- +$102,000
- SEC form
- 4
- Accepted by SEC
- 13 Apr 2022, 16:05:46 UTC
- Prior SEC filing
- 28 Feb 2022
- Next SEC filing
- 09 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dror Bashan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 13 Apr 2022.
Change
- Previous filing in this sequence was filed on 28 Feb 2022.
- Current net transaction value: +$102,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLX
transaction
Common Stock
Purchase
- Transaction value
- $102,000
- Shares
- +68,000
- Change %
- Price
- $1.50
- Shares after
- 68,000
- Date
- 11 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
PLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,085,458
- Date
- 11 Apr 2022
- Ownership
- By Trust
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reporting person holds the shares in an account with his spouse as joint tenants.
Footnote F2
Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.